SLS · XBRL financial data
SELLAS Life Sciences Group financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (SLS's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 1,900 | 7,600 | 1,000 | 0 | — | — |
| Cost of goods and services sold | 0 | 200 | 100 | 0 | 0 | 0 |
| Research and development | 9,282 | 15,674 | — | — | — | — |
| Selling, general and administrative | 9,600 | 11,320 | 12,582 | 13,862 | 12,417 | 12,252 |
| Operating income (loss) | (16,982) | (25,294) | (41,950) | (37,869) | (31,513) | (28,274) |
| Income tax expense (benefit) | (17) | (237) | 0 | 0 | 0 | 0 |
| Net income (loss) | (16,757) | (20,699) | (41,301) | (37,340) | (30,881) | (26,863) |
| Earnings per share, basic USD per share | (2.11) | (1.34) | (2.13) | (1.34) | (0.50) | (0.25) |
| Earnings per share, diluted USD per share | (2.11) | (1.34) | (2.13) | (1.34) | (0.50) | (0.25) |
| Weighted average shares, basic thousands of shares | 7,977 | 15,481 | 19,396 | 27,777 | 61,202 | 109,051 |
| Weighted average shares, diluted thousands of shares | 7,977 | 15,481 | 19,396 | 27,777 | 61,202 | 109,051 |
- † Share count changed about 2x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 2x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (SLS's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 35,302 | 21,355 | 17,125 | 2,530 | 13,886 | 71,793 |
| Accounts receivable | — | 0 | — | — | — | — |
| Prepaid and other current assets | 395 | 1,589 | 531 | 542 | 2,341 | 3,318 |
| Total current assets | 36,925 | 23,044 | 17,756 | 3,172 | 16,327 | 75,211 |
| Right-of-use asset | 896 | 723 | 874 | 858 | 925 | 963 |
| Goodwill | 1,914 | 1,914 | 1,914 | 1,914 | 1,914 | 1,914 |
| Total assets | 46,049 | 26,275 | 20,943 | 6,219 | 19,432 | 78,345 |
| Accounts payable | 4,657 | 2,144 | 3,357 | 5,639 | 3,500 | 2,948 |
| Accrued liabilities | 1,913 | 2,640 | 6,286 | 7,650 | 5,466 | 3,525 |
| Total current liabilities | 12,336 | 4,982 | 15,515 | 13,735 | 9,510 | 7,017 |
| Lease liability, non-current | 825 | 610 | 573 | 460 | 457 | 457 |
| Total liabilities | 18,088 | 5,928 | 16,092 | 14,195 | 9,967 | 7,474 |
| Accumulated deficit | (117,904) | (138,603) | (179,904) | (217,244) | (248,125) | (274,988) |
| Total stockholders' equity | 27,961 | 20,347 | 4,851 | (7,976) | 9,465 | 70,871 |
| Total liabilities and equity | 46,049 | 26,275 | 20,943 | 6,219 | 19,432 | 78,345 |
| Common shares outstanding (cover page) thousands of shares | 15,085 | 15,906 | 28,303 | 56,268 | 90,847 | 179,583 |
- † Share count changed about 2x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 2x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (SLS's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (16,757) | (20,699) | (41,301) | (37,340) | (30,881) | (26,863) |
| Stock-based compensation | 578 | 1,011 | 1,726 | 2,094 | 1,564 | 1,956 |
| Net cash from operating activities | (10,417) | (26,021) | (23,809) | (31,410) | (35,402) | (28,389) |
| Net cash from investing activities | — | 0 | (4,500) | (5,500) | 0 | — |
| Proceeds from issuing common stock | 29,599 | 9,005 | 1,048 | 289 | 0 | — |
| Net cash from financing activities | 38,442 | 12,074 | 24,079 | 22,315 | 46,758 | 86,296 |
| Net change in cash | 28,025 | (13,947) | (4,230) | (14,595) | 11,356 | 57,907 |
- † Share count changed about 2x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 2x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| SELLAS Life Sciences Group | 138,343 | not reported | (7,588)* | 201.9M | 18.2 quarters | 10-QJun 30, 2026 |
| Precigen | 16,329 | 54,978 | (17,809)* | 358.0M | 2.1 quarters | 10-QJun 30, 2026 |
| Lifecore Biomedical | 17,241 | not reported | (2,189)* | 37.9M | 7.9 quarters | 10-QJun 30, 2026 |
| Perspective Therapeutics | 48,488 | not reported | (20,650)* | 114.2M | 11.5 quarters | 10-QJun 30, 2026 |
| Rocket Pharmaceuticals | 224,507 | 0 | (39,613)* | 109.8M | 7.2 quarters | 10-QJun 30, 2026 |
| Natures Sunshine Products | 82,503 | 116,985 | 835* | 17.6M | — | 10-QJun 30, 2026 |
| Sagimet Biosciences | 165,896 | not reported | (11,099)* | not reported | 21.6 quarters | 10-QJun 30, 2026 |
| Tvardi Therapeutics | 15,765 | not reported | (9,228)* | 13.3M | 1.7 quarters | 10-QJun 30, 2026 |
| Aldeyra Therapeutics | 45,090 | not reported | (4,589)* | 60.3M | 9.8 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.